This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Ventricular dysfunction in group 1 pulmonary hypertension

  • Research type

    Research Study

  • Full title

    Evaluation of right ventricular performance in response to heart rate reduction in pulmonary hypertension using pressure volume loop analysis at rest and on exercise

  • IRAS ID

    219677

  • Contact name

    Colm McCabe

  • Contact email

    c.mccabe2@rbht.nhs.uk

  • Sponsor organisation

    Royal Brompton Hospital

  • Duration of Study in the UK

    1 years, 5 months, 21 days

  • Research summary

    Pulmonary hypertension (PH) is an umbrella term for raised blood pressure in the lungs. Among its subdivisions, idiopathic pulmonary arterial hypertension (IPAH) and congenital heart disease associated - pulmonary arterial hypertension (CHD-PAH) can both be associated with thickening and obstruction of the arteries in the lungs leading ultimately to failure of pump function of the right ventricle (RV), responsible for generating blood flow to the lungs.

    This is a prospective study of right ventricular performance using cardiac catheter - derived haemodynamic indices aimed at improving understanding of how the RV adapts differently in sub-types of PH. First and foremost, the study will evaluate RV filling and contractile responses at rest and on exercise interrogating the energetic performance of the RV using exercise pressure volume analysis. The study further evaluates the RV's response to heart rate reduction achieved by single dose administration of Ivabradine (a drug that lowers heart rate by inhibiting the heart's intrinsic pacemaker function) as there is a strong scientific rationale for suspecting heart rate reduction favourably alters the energetic profile of RV performance. In PH, the resistance to forward blood flow in the lungs is abnormally high and this study should provide further insight into mechanisms of RV adaptation that are central to prognosis in this life-limiting disease.

  • REC name

    London - Surrey Research Ethics Committee

  • REC reference

    17/LO/1686

  • Date of REC Opinion

    14 Nov 2017

  • REC opinion

    Further Information Favourable Opinion